Mentioned in

alopecia

References in periodicals archive

(NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced results from its Phase 2 clinical trial of ATI-501 (AUAT-201 Oral), an investigational oral Janus Kinase (JAK) 1/3 inhibitor, in subjects with alopecia areata (AA).

Aclaris Therapeutics Announces Phase 2 Clinical Trial of ATI-501 Oral in Patients with Alopecia Areata Met Primary Endpoint

[5] There are several publications reporting high dose pulse steroid treatment for alopecia areata. [6-9]

DERMOSCOPIC EVALUATION OF THERAPEUTIC RESPONSE IN ALOPECIA AREATA

(NASDAQ: CNCE) has completed patient enrollment of an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata, the company said.

Concert Pharmaceuticals Completes Enrollment in Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata

Studies show that in Alopecia areata, failure of this immune privilege results in type 1 cellular immunity mediated by cytotoxic T lymphocytes which attack hair follicles and prevent them from entering the growing phase of the hair cycle.3 These cytotoxic T lymphocytes depend on the Interleukin-15 pathway which utilizes Janus Kinase (JAK) proteins for downstream signaling.

Use of JAK inhibitors in treatment of Alopecia areata

United States-based Pfizer has commenced a phase 2b/3 clinical trial of PF-06651600, an oral JAK3 inhibitor, intended to treat patients with moderate to severe alopecia areata, it was reported on Friday.

Pfizer commences alopecia areata phase 2b/3 clinical trial

Alopecia areata affects an estimated 75 million people worldwide on a chronic and recurring basis, including 37 million with alopecia totalis or universalis, according to Dr.

JAK inhibitors mark new era for alopecia areata therapy

Keywords: Multiple autoimmune syndrome, lichen planus, vitiligo, alopecia areata, isotopic phenomenon.

Multiple autoimmune syndrome with isotopic phenomenon: association of lichen planus, vitiligo and alopecia areata with autoimmune hepatitis

Specifically, the analysis found, alopecia areata patients are at risk for any mental health disorder, anxiety disorders, attention-deficit/hyperactivity disorder, dementia, mood disorders, personality disorders, and suicide or intentionally self-inflicted injury.

Alopecia areata linked to anxiety, ADHD, dementia, and other disorders

Oxidative Stress in Alopecia Areata and its Association with Disease Severity, Treatment and Autoimmunity.

A Marker for Evaluation of Oxidative Stress in Patients with Alopecia Areta: Thiol-Disulphide Homeostasis/Alopesi Areata Tanili Hastalarda Oksidatif Stresin Degerlendirilmesinde Bir Belirtec: Tiyol-Disulfid Homeostazi

In a previous study, the researchers identified a genetic signal, which is a gene called named IKZF1- in alopecia areata.

Hair loss gene is key to improved cancer immunotherapy

CHICAGO -- How do you talk to your alopecia areata patients and their families about hair loss?

How to get through the tough talks about alopecia areata with children